PPCB · Propanc Biopharma Inc
United States · RS rating 2 · As of 2026-11-03
| Price | 1.71 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 2 / 2 / 2 / 2 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 4 / 40 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +23.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +99.4% |
| Market cap (USD) | $2.5M |